Table 3 The eight drug candidates identified by multiple omics analysis in this study.
From: Drug repositioning for dengue haemorrhagic fever by integrating multiple omics analyses
Name | Activity | Disease | ATC | KEGG DGroup |
|---|---|---|---|---|
Estradiol | Menstruation disorder agent, Estrogen receptor agonist | Postmenopausal osteoporosis | Genito urinary system and sex hormones (G) | Other, Cyp substrate |
Etoposide | Antineoplastic, Topoisomerase II inhibitor | Testicular tumors, Small cell lung cancer | Antineoplastic and immunomodulating agents (L) | Other, Cyp substrate |
Resveratrol | Antiinflammatory agents | Herpes labialis infections | ||
Simvastatin | Antihyperlipidemic, HMG-CoA reductase inhibitor | Hyperlipidemia, Heterozygous familial hypercholesterolemia | Cardiovascular system (C) | Cardiovascular agent, Cyp substrate |
Sirolimus | Antineoplastic, Immunosuppressant, mTOR inhibitor | Lymphangioleiomyomatosis | Antineoplastic and immunomodulating agents (L), Sensory organs (S) | Antineoplastic, Transporter substrate |
Valproic acid | Anticonvulsant | Seizure disorders, Migraine headache. | Nervous system (N) | Neuropsychiatric agent, Other, Cyp substrate |
Vorinostat | Antineoplastic, Histone deacetylase inhibitor | Cutaneous T-cell lymphoma | Antineoplastic and immunomodulating agents (L) | |
Y-27632 | ROCK family kinase inhibitor, hiPS/ES Cell death inhibitor |
